Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2102 vs Chemotherapy in HER2-Low Recurrent/Metastatic Breast Cancer
NCT06561607Phase 3Active, not recruiting
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Oct 2024
- Primary completion
- Jan 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of TQB2102 in breast cancer (2 arms), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoint: Progression-Free Survival up to 25 months. Started Oct 2024; status: active, not recruiting.
02
Drugs
TQB2102
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06561607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06561607.